Soufflé Therapeutics launched with a $200 million Series A to develop cell‑targeted RNA therapeutics, backed by founders and industry veterans including Moderna co‑founder Bob Langer. The company plans to engineer siRNA medicines that achieve precise, cell‑specific delivery to broaden RNA modalities into indications beyond current reach. Soufflé’s sizable raise and Big Pharma partnerships signal investor appetite for specialty RNA platforms that promise improved targeting and therapeutic windows. The firm will invest proceeds into discovery, preclinical candidate selection and platform expansion. The debut adds to a wave of large, well‑funded RNA startups seeking to capitalize on delivery and specificity advances and underscores continued capital flows into next‑generation nucleic acid therapeutics.